Page 1

August 6 , 2026 CORBUS PHARMACEUTICALS Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update • Obtained FDA clearance to proceed with registrational study ( TEMPO - 1 ) of CRB - 701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 • Concluded last patient last visit in CANYON - 1 Phase 1b study ( n = 240 ) of CRB - 913 in obesity and on track to report data in September 2026 Appointed new Chief Medical Officer , Chief Business Officer , and Board Member to strengthen senior leadership and guide the Company through registrational studies and commercialization readiness -- NORWOOD , Mass . , Aug. 06 , 2026 ( GLOBE NEWSWIRE ) Corbus Pharmaceuticals Holdings , Inc. ( NASDAQ : CRBP ) ( " Corbus " or the " Company " ) , a clinical - stage company focused on developing new therapies in oncology and obesity , today provided a corporate update and reported financial results for the 2026 second quarter ended June 30 , 2026 . " We've continued to build momentum as we prepare for two potentially impactful clinical development milestones in September : commencing enrollment of TEMPO - 1 , our Phase 3 study of CRB - 701 in oropharyngeal cancer , and the data readout of CANYON - 1 , our Phase 1b study of CRB - 913 in obesity . Both programs represent opportunities to address areas of significant unmet medical need , " said Yuval Cohen , Ph.D. , Chief Executive Officer of Corbus . " CRB - 701 has the potential to bring a much - needed therapeutic option for the growing oropharyngeal cancer patient population , for whom approved and other investigational therapies have shown little promise . CRB - 913 is a unique daily oral obesity drug candidate with a mechanism of action entirely orthogonal to the GLP - 1 class and with the potential for both weight loss and long - term weight management . We look forward to a productive second half of 2026 as we work to improve patient outcomes and generate meaningful value for shareholders . " Key Corporate and Program Updates CRB - 701 is a next - generation , highly stable Nectin - 4 targeting antibody drug conjugate ( ADC ) being developed to treat oropharyngeal squamous cell carcinoma ( OPSCC ) , a type of head and neck squamous cell carcinoma ( HNSCC ) , as well as cervical cancer . The U.S. Food and Drug Administration ( FDA ) has granted Fast Track designations to CRB - 701 for the treatment of both cancer types . CRB - 701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China .